Loncastuximab and Rituximab for Post-Transplant Lymphoma
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two immunotherapy drugs (loncastuximab tesirine and rituximab) to treat a type of lymphoma (blood cancer) that develops after solid organ transplantation. The goal is to see if this treatment can help control the cancer while being safe for transplant patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have been diagnosed with B-cell PTLD (a blood cancer that develops after organ transplant) confirmed by biopsy
- Your cancer can be measured on imaging scans (PET-CT or MRI)
- Your blood counts and organ function (liver and kidney) are adequate enough to safely receive treatment
- You are not pregnant, not breastfeeding, and willing to use effective birth control if you could become pregnant
- You have not had major surgery in the past 4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-drug combination (loncastuximab tesirine and rituximab) as a short-term "bridge" treatment for people with large B-cell lymphoma who are waiting to receive standard CAR-T cell therapy. The goal is to control the lymphoma before the CAR-T cells can be given.
This trial tests a combination of radiation therapy to specific tumor sites followed by a bispecific antibody (a type of immunotherapy that targets cancer cells). It's designed for people with diffuse large B-cell lymphoma that has not responded to or has come back after at least two prior treatments.
This trial studies tafasitamab plus rituximab to treat a type of lymphoma called post-transplant lymphoproliferative disorder (PTLD) in adults after a solid organ transplant. It’s aimed at helping stop the PTLD when it can be measured and before you’ve had PTLD treatment beyond limited measures like steroid or reducing anti-rejection drugs.
This trial tests a new drug called epcoritamab for people whose PTLD (a type of lymphoma that can happen after an organ transplant) has come back or hasn't been helped by standard treatments. The goal is to see if epcoritamab can shrink or control the cancer.
This study tests whether a medication called rituximab can help prevent a type of cancer (PTLD) that sometimes develops in transplant patients whose body is fighting a reactivated virus (EBV). You may qualify if you've had an organ transplant, have high levels of EBV in your blood, and haven't yet developed this cancer.
This Phase 2 study tests whether loncastuximab, combined with rituximab, can shrink and control follicular lymphoma that has come back or not responded to prior treatment. It may help people who still have active disease that needs treatment and meet specific scan and blood test requirements.
Hear when a new Post-Transplant Lymphoproliferative Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.